Valerie Simone Honndorf1, Sally-Ann Ricketts2, Jane Halliday2, Hans F. Wehrl3, Stefan Wiehr3, Damaris Kukuk3, Maren K. Koenig3, Mareike Lehnhoff3, Julia Mannheim3, Gerald Reischl4, Bernd J. Pichler3
1Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation , University of Tuebingen, Tuebingen, Germany; 2Imaging, Translational Sciences, AstraZeneca, Alderley Park, Macclesfield, Cheshire, United Kingdom; 3Laboratory for Preclinical Imaging & Imaging Technology of the Werner Siemens-Foundation, University of Tuebingen, Tuebingen, Germany; 4Radiopharmacy & PET-Center, University of Tuebingen, Tuebingen, Germany
Diffusion-weighted MRI in combination with PET is a powerful tool to monitor cancer therapy. We show the correlation between the [18F]FLT-PET imaging and the apparent diffusion coefficient (ADC) in a colon cancer mouse model in a control group and a group treated with docetaxel. We found that the ADC maps reveal an inverse spatial correlation to the [18F]FLT uptake in the tumor demonstrating the relationship between water diffusion in necrotic regions and the thymidine kinase activity in proliferating cells. Such complementarities between MR diffusivity and [18F]FLT-PET open new insights for the usability of diffusion-weighted imaging as diagnostic tool in oncology.